Following the successful completion of a US$45m fund raising ApaTech, a world leader in applying the science of silicon to bone graft technology, is delighted to announce several senior management appointments and organizational changes.
In anticipation of a major recruitment campaign across multiple functions and geographies, Lynn Lester joins ApaTech as VP Human Resources reporting to CEO Simon Cartmell. Lynn joins from Cambridge Antibody Technology plc where she was SVP Human Resources and Business Operations responsible for the growth of this biologics division of AstraZeneca plc in the UK and USA.
Dr Tom Buckland is promoted to the position of VP Research and Development, an extension of his current research responsibilities and will continue to report to CEO Simon Cartmell.
Dr Jim Cassidy relinquishes his clinical development responsibilities to focus on the regulatory aspects of new product development as VP Regulatory and Scientific Affairs, a role created in recognition of the importance of regulatory interaction for new products. A search is underway for a VP Clinical Development reporting to the CEO Simon Cartmell.
Rick Thomas joins as Area Director N Europe, responsible for sales activities in UK, Eire, Benelux and Scandinavia. Rick joins from Medtronic Inc where he was UK Sales Manager for Kyphon. In a parallel move Dr Joerg Maassen is promoted to Area Director DASA responsible for the sales activities in Germany, Austria, Switzerland and Eastern Europe. Rick and Joerg will report to the yet to be appointed VP OUS.
Mitch White and Mark Bossard are appointed VP Sales for the Mid America and Central regions of the US respectively. Mitch joins from VertiFlex Inc and Mark from Isotis Inc. Both Mitch and Mark will report to Steve Czick, President ApaTech Inc.
Commenting on these appointments, CEO Simon Cartmell said “to realize its goals ApaTech will have to recruit 100 people in the next 12 months in all disciplines and territories. These appointments and changes are the beginning of a period of extraordinary growth for the company. To reflect our technology leadership in applying the science of silicon to the field of bone grafting and our differentiated products, we seek truly extraordinary people to become part of the ApaTech team. I am confident we have made a great start with these appointments because the individuals fully reflect our values of action, passion and ambition”.
Ends
Further Information:
ApaTech
Simon Cartmell, CEO +44 (0)20 8731 4640
simon.cartmell@apatech.com www.apatech.com
Notes to Editors:
About ApaTech
ApaTech Limited, based in London, England, Foxborough, Mass. is a world leader in bone graft technologies. Founded in 2001 and based on research and intellectual property from London and Cambridge Universities, ApaTech has introduced a novel silicate substituted calcium phosphate bone graft material, Actifuse, globally. The company believes that Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive and osteo-stimulatory activities and demonstrates the Company’s leadership in applying the science of silicon to bone graft technologies.
The Company raised £11.5m of venture capital from 3i plc and MTI and £3.5m of debt from Noble Venture Finance in 2001-7 and a growth equity round of $45m in May 2008. ApaTech commercializes its products, Actifuse and ApaPore in 21 countries around the world and is achieving rapid sales growth, with sales of $15.5m in 2007.
ApaTech has locations in Elstree, UK, Berlin, Germany and Foxborough, MA, USA. The Company sells its products in the US, UK, Germany and 18 other countries around the world. ApaTech was recently recognized as Britain’s fastest growing medical technology company in the 2007 Sunday Times Fast Track 100 fastest growing private companies review.
